glycyrrhiz
acid
gl
herbal
drug
broad
spectrum
antivir
activ
pharmacolog
effect
multipl
site
action
previous
show
gl
inhibit
epsteinbarr
viru
ebv
infect
vitro
interf
earli
step
ebv
replic
cycl
possibl
attachmentpenetr
test
effect
gl
deriv
ebv
infect
score
number
cell
express
viral
antigen
quantifi
ebv
dna
copi
number
superinfect
raji
cell
deriv
made
either
transform
gl
carboxyl
hydroxyl
group
conjug
amino
acid
residu
carbohydr
part
identifi
seven
compound
activ
ebv
show
dosedepend
inhibit
determin
assay
among
activ
compound
introduct
amino
acid
residu
gl
carbohydr
part
enhanc
antivir
activ
three
seven
activ
compound
howev
glu
oh
ome
substitut
glu
ome
ome
antivir
activ
complet
abolish
introduct
potassium
ammonium
salt
gl
reduc
antivir
activ
signific
effect
cytotox
potent
sodium
salt
lost
antivir
activ
metabol
product
gl
acid
ga
activ
ebv
parent
compound
gl
concomitantli
exhibit
increas
cytotox
result
decreas
therapeut
index
glycyrrhiz
acid
gl
one
bioactiv
compound
licoric
root
glycyrrhiza
radix
compos
one
molecul
glycyrrhetin
acid
ga
steroidlik
structur
two
molecul
glucuron
acid
oral
administr
intraven
inject
gl
hydrolyz
glucuronidas
intestin
bacteria
activ
principl
aglycon
absorb
blood
takeda
et
al
gl
ga
shown
possess
sever
benefici
pharmacolog
activ
dirnagl
et
al
shibata
abe
et
al
armanini
et
al
cherng
et
al
cinatl
et
al
fior
et
al
includ
antiulc
effect
antiinflammatori
activ
fujisawa
et
al
interferon
ifn
induct
antihepatotox
effect
chan
et
al
gumpricht
et
al
zheng
lou
antitumor
activ
hibasami
et
al
activ
rang
virus
lin
correspond
author
tel
fax
email
address
jclin
mailtcuedutw
jc
lin
cinatl
et
al
cranc
et
al
briolant
et
al
cherng
et
al
hoever
et
al
clinic
gl
use
treat
patient
chronic
activ
hepat
van
rossum
et
al
bean
coon
ernst
previou
year
shown
mani
nucleosid
analog
select
inhibit
replic
epsteinbarr
viru
ebv
vitro
lin
et
al
lin
et
al
lin
et
al
lin
et
al
lin
et
al
lin
et
al
lin
machida
mar
et
al
review
see
gershburg
pagano
lin
molecular
target
nucleosid
analog
virusencod
dna
polymeras
recent
report
gl
activ
dosedepend
fashion
ebv
replic
superinfect
raji
cell
lin
result
also
indic
gl
interfer
earli
step
ebv
replic
cycl
possibl
adsorpt
andor
penetr
lin
thu
gl
repres
new
class
antiebv
compound
mode
action
differ
nucleosid
analog
inhibit
viral
dna
polymeras
present
studi
extend
previou
find
search
potent
compound
ebv
test
antivir
activ
gl
deriv
synthes
laboratori
report
identif
seven
activ
compound
ebv
infect
vitro
elucid
structureact
relationship
glycyrrhiz
acid
glycyrrhizin
gl
acid
ga
purchas
sigmaaldrich
chemi
gmbh
germani
synthesi
gl
deriv
report
previous
baltina
baltina
et
al
kondratenko
et
al
laminoacid
use
synthesi
gl
glycopeptid
unless
otherwis
specifi
drug
dissolv
phosphatebuff
salin
ph
chemic
structur
shown
chart
latent
ebvinfect
nonviru
produc
cell
line
raji
maintain
cellsml
rpmi
medium
contain
fetal
calf
serum
fc
supplement
iu
penicillinml
g
streptomycinml
describ
previous
lin
et
al
highli
product
virusproduc
cell
line
ls
deriv
lowserum
clone
lin
maintain
cultur
medium
raji
cell
except
serum
concentr
reduc
viral
stock
prepar
cultur
ls
treat
tpa
concentr
ngml
lin
briefli
ls
cell
induc
tpa
day
without
addit
medium
cell
remov
centrifug
g
min
viru
pellet
cellfre
supernat
fluid
centrifug
g
min
rotor
ivan
sorval
inc
centrifug
bottl
swab
remov
residu
medium
chart
viru
pellet
suspend
rpmi
medium
viral
suspens
clarifi
remov
cellular
debri
filter
filter
store
c
assay
system
drug
effect
use
raji
cell
superinfect
ls
viru
result
reactiv
latent
ebv
infect
replic
viru
raji
cell
first
propag
medium
contain
subeffect
dose
compound
superinfect
lin
raji
cell
grow
exponenti
pellet
resuspend
ml
rpmi
medium
contain
fc
appropri
concentr
drug
specifi
unit
ebv
earli
antigen
ea
induc
viru
ad
cell
one
unit
viru
defin
amount
viru
capabl
induc
infect
raji
cell
express
ea
h
adsorpt
c
co
incub
cell
pellet
suspend
ml
medium
incub
continu
h
level
ebv
earli
antigen
ea
viral
capsid
antigen
vca
monitor
indirect
immunofluoresc
assay
ifa
h
infect
ebvposit
sera
npc
patient
specif
sera
ebv
eavca
confirm
western
blot
report
previous
lin
pagano
detail
protocol
ifa
describ
previous
lin
briefli
superinfect
raji
cell
smear
slide
fix
methanol
min
room
temperatur
fix
cell
first
react
npc
patient
serum
follow
fluoresceinconjug
goat
antihuman
igg
h
l
santa
cruz
biotechnolog
inc
counterstain
dapi
gml
pb
min
dark
slide
analyz
fluoresc
microscop
drug
effect
ebv
dna
superinfect
raji
cell
determin
use
realtim
quantit
pcr
system
toward
bamhiw
fragment
region
ebv
genom
describ
lo
et
al
realtim
quantit
pcr
base
continu
optic
monitor
progress
fluorogen
pcr
reaction
system
amplif
primer
use
convent
pcr
toward
bamhiw
duallabel
fluorogen
hybrid
probe
fam
cacacactacacacacccacccgtctc
tamra
fluoresc
probe
contain
block
phosphat
group
prevent
probe
extens
pcr
effect
gl
deriv
raji
cell
cytotox
carri
mtt
bromid
thiazolyl
blue
cellprolif
kit
roch
mannheim
germani
raji
cell
seed
well
plate
treat
variou
concentr
drug
day
l
steril
mtt
dye
ad
cell
incub
h
c
follow
ad
l
acid
isopropanol
hcl
isopropanol
spectrometr
absorb
nm
formazan
dye
measur
absorb
nm
refer
determin
dosedepend
effect
gl
deriv
raji
cell
superinfect
ls
viru
presenc
variou
concentr
compound
express
ea
vca
monitor
ifa
h
superinfect
repres
result
compound
xv
shown
fig
without
drug
treatment
approxim
infect
cell
becam
posit
viral
antigen
fig
panel
presenc
drug
dosedepend
inhibit
express
viral
antigen
observ
fig
panel
b
c
e
concentr
drug
requir
inhibit
ebv
antigen
express
ec
determin
plot
drug
concentr
viral
antigenposit
cell
assum
nodrug
control
fig
show
graphic
quantit
compound
xv
ec
determin
graph
approxim
shown
tabl
seven
gl
deriv
activ
ebv
infect
ec
rang
activ
compound
exhibit
dosedepend
inhibit
manner
parent
compound
gl
use
posit
drug
control
addit
ga
metabolit
gl
also
test
parallel
deriv
interest
note
ga
effect
compound
block
ebv
infect
ec
lower
gl
howev
ga
approxim
toxic
cc
gl
cc
cytotox
gl
deriv
determin
microtit
plate
mtt
assay
result
express
concentr
compound
decreas
cell
viabil
cc
drug
control
tabl
compound
exhibit
variabl
cytotox
cc
rang
precis
determin
drug
effect
ebv
dna
copi
number
measur
use
realtim
quantit
pcr
system
amplifi
dna
segment
bamhiw
fragment
region
ebv
genom
lo
et
al
dosedepend
inhibit
viral
genom
copi
number
compound
xv
observ
fig
ec
obtain
method
approxim
contrast
determin
ifa
tabl
data
obtain
pcr
ifa
shown
side
side
tabl
note
ec
valu
obtain
realtim
quantit
pcr
approxim
lower
obtain
ifa
howev
inhibitori
profil
compound
remain
unchang
indic
ifa
reliabl
quantit
pcr
method
initi
drug
screen
evalu
antivir
agent
effect
ebv
hamper
lack
permiss
cell
system
replic
viru
superinfect
raji
cell
viru
result
shutdown
host
cell
dna
synthesi
stimul
viral
dna
replic
lytic
antigen
synthesi
product
viru
previous
shown
percentag
eaand
vcaposit
cell
directli
proport
amount
ebv
dna
cell
lin
furthermor
also
demonstr
gl
block
ebv
replic
earli
step
viral
replic
cycl
howev
gl
effect
ebv
dna
spontan
virusproduc
cell
line
latent
infect
nonvirusproduc
raji
cell
lin
lack
effect
gl
raji
cell
alreadi
infect
consist
propos
mechan
gl
action
ie
inhibit
viru
attachmentpenetr
thu
superinfect
raji
cell
repres
use
system
evalu
compound
block
earli
step
ebv
replic
cycl
result
indic
gl
sever
deriv
highli
select
antivir
action
inhibit
ebv
infect
concentr
far
cytotox
concentr
demonstr
previous
lin
pretreat
cell
subeffect
dose
gl
markedli
reduc
cytotox
effect
decreas
amount
drug
approxim
reduct
need
reach
effect
level
mark
reduct
ec
obtain
pretreat
cell
subeffect
dose
compound
clinic
implic
regard
prophylact
therapeut
effect
among
seven
activ
compound
tabl
three
contain
amino
acid
residu
gl
carbohydr
part
alaom
contain
glycopeptid
xii
glu
oh
ome
contain
glycopeptid
xiii
leu
contain
glycopeptid
xv
activ
ebv
howev
compound
xii
ec
xv
ec
approxim
activ
ebv
compound
xiii
ec
cc
valu
glycopeptid
xii
xiii
xv
respect
result
therapeut
index
contrast
two
glycopeptid
contain
compound
ix
exhibit
activ
ebv
concentr
mm
interestingli
glu
oh
ome
substitut
glu
ome
ome
compound
xiv
antivir
activ
complet
abolish
introduct
hydroxyl
methoxyl
group
r
posit
aglycon
moieti
gl
compound
ii
iii
show
antivir
activ
compound
ix
xii
contain
hydroxyl
group
r
posit
ga
molecul
differ
substitut
r
posit
carbohydr
part
gl
compound
xii
alaom
group
r
posit
show
good
antivir
activ
wherea
substitut
compound
ix
alaobu
group
posit
abolish
antivir
activ
interestingli
substitut
r
posit
ga
ly
z
oh
compound
v
lglu
ome
ome
compound
xiv
confer
antivir
activ
thu
appear
modif
carbohydr
moieti
gl
rather
r
posit
aglycon
may
affect
antivir
activ
find
may
provid
lead
develop
activ
antivir
compound
two
commerci
avail
compound
gl
ga
test
parallel
semisynthet
gl
deriv
unexpectedli
ga
metabol
product
gl
activ
ec
ebv
parent
compound
ec
toxic
cc
gl
cc
result
therapeut
index
respect
introduct
potassium
compound
vi
ammonium
salt
compound
vii
gl
reduc
antivir
activ
signific
effect
cytotox
compound
viii
deriv
potent
ec
cc
result
therapeut
index
contrast
sodium
salt
compound
xi
lost
antivir
activ
compar
compound
x
previou
studi
indic
sugar
moieti
gl
essenti
antisarscov
activ
present
studi
clearli
demonstr
compound
vi
vii
viii
x
xii
xiii
xv
activ
inhibitor
ebv
infect
contain
sugar
moieti
summari
among
newli
identifi
analog
four
show
better
equal
activ
parent
gl
recent
demonstr
gl
interfer
earli
step
ebv
replic
cycl
possibl
attachmentpenetr
lin
howev
possibl
mechan
gl
may
also
involv
inhibit
ebv
replic
gl
ga
shown
elicit
dosedepend
increas
product
level
ino
mrna
macrophag
jeong
kim
host
defens
molecul
antimicrobi
activ
varieti
pathogen
includ
virus
previou
studi
indic
involv
maintain
ebv
latenc
inhibit
ebv
reactiv
mannick
et
al
gao
et
al
molecular
mechan
underli
gl
inhibit
viral
attach
well
understood
complement
protein
call
breakdown
product
complement
receptor
call
type
complement
receptor
express
matur
b
lymphocyt
b
lymphocyt
recogn
antigen
antigen
receptor
simultan
recogn
bound
antigen
complement
receptor
b
cell
activ
major
ebv
outer
envelop
glycoprotein
ligand
nemerow
et
al
tanner
et
al
blymphocyt
surfac
protein
bind
nemerow
et
al
mediat
viru
attach
receptor
human
b
lymphocyt
recent
studi
indic
complement
glbind
protein
kawakami
et
al
synthet
peptid
correspond
two
region
similar
amino
acid
sequenc
complement
protein
use
identifi
receptor
bind
epitop
peptid
correspond
n
terminu
edpgffnvei
bound
purifi
posit
neg
b
lymphoblastoid
cell
line
nemerow
et
al
peptid
sequenc
edpgffnvei
similar
peptid
sequenc
edpgkqlynvea
compon
complement
bind
nemerow
et
al
synthet
peptid
contain
lynvea
sequenc
block
bind
lambri
et
al
wherea
peptid
contain
edpgffnvea
sequenc
block
ebv
infect
nemerow
et
al
nemerow
et
al
taken
togeth
studi
open
possibl
inhibitori
effect
gl
could
part
due
blockad
ebv
receptor
antiebv
activ
glycopeptid
xii
xiii
xv
could
attribut
similar
amino
acid
residu
peptid
sequenc
edpgkqlynva
compon
complement
bind
ascertain
possibl
would
requir
studi
current
investig
target
perspect
drug
might
candid
treatment
ebv
infect
fall
two
group
review
see
ref
gershburg
pagano
lin
first
group
target
viral
dna
polymeras
includ
acycl
nucleosid
analogu
acyclovir
ganciclovir
penciclovir
valaciclovir
valganciclovir
famciclovir
acycl
nucleotid
analogu
cidofovir
adefovir
pyrophosph
analogu
phosphonoform
acid
phosphonoacet
acid
possibl
second
group
contain
compound
mix
natur
distinct
structur
maribavir
uracil
indolocarbazol
nigci
mechan
action
drug
still
studi
involv
inhibit
viral
dna
polymeras
molecular
target
herpesvirus
nucleosid
analog
virusencod
dna
polymeras
mode
action
gl
deriv
differ
therapeut
prophylact
effect
gl
chronic
activ
viral
hepat
bean
coon
ernst
shibata
van
rossum
et
al
inhibitori
effect
ebv
replic
observ
present
studi
togeth
rel
lack
toxic
cellular
level
suggest
gl
select
deriv
may
worth
evalu
efficaci
safeti
treatment
activ
ebv
infect
